Soft Tissue Sarcoma: The Predominant Primary Malignancy in the Retroperitoneum by Dalen, Thijs van et al.
Correspondence to: Th. van Dalen, Department of Surgery, Universitair Medisch Centrum, Room G04.228, Heidelberglaan 100, 3584
CX Utrecht, The Netherlands. E-mail: nounou@knoware.nl
1357± 714X print/1369± 1643 online/01/010005± 04 ½  2001 Taylor & Francis Ltd
DOI: 10.1080/13577140120048881
Sarcoma (2001) 5, 5± 8
ORIGINAL ARTICLE
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Abstract
Purpose. In the clinical work-up of a retroperitoneal mass, the diagnosis of soft tissue sarcoma is often not considered. Inci-
dence rates of various malignant and benign retroperitoneal tumours were studied to determine the incidence of soft tissue
sarcoma in comparison with other neoplasms in the retroperitoneal space.
Method. Nation-wide data on retroperitoneal tumours, collected prospectively over a 5-year period (1 January 1989± 1 January
1994), were supplied by the Netherlands Cancer Registry and The Dutch Network and National Database for Pathology.
Results. Seven hundred and six patients with a primary retroperitoneal neoplasm were identified; 566 patients had a malig-
nant tumour (80%). A soft tissue sarcoma (STS) was the most frequently diagnosed malignant tumour (n = 192), The age-
standardised incidence of retroperitoneal STS was 2.5 per million person-years. The male/female ratio for STS was 0.73. In
females, STS comprised 41% of all malignant retroperitoneal tumours, carcinoma of unknown primary tumour site (CUP)
comprised 31%, and malignant lymphomas (ML) comprised 22%, whereas in males these values were 28% (STS), 30%
(CUP), and 32% (ML), respectively.
Discussion. Soft tissue sarcomas, albeit rare, are relatively common primary tumours in the retroperitoneum, especially in
women.
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Introduction
Primary tumours in the retroperitoneal space that
do not originate from the retroperitoneal viscera
are uncommon. Soft tissue sarcomas (STS) arise
occasionally in the retroperitoneum, but are so rare
that the diagnosis is not always taken into account
by a clinician who is investigating a patient with a
retroperitoneal  neoplasm.  In  a  population-based
study on the clinical presentation of patients with a
retroperitoneal STS, more than  one-third  of  the
patients  was  initially  diagnosed erroneously,  and
operated for a tumour that was not considered to
be a STS.1
Data on the frequency of STS and other primary
malignancies  in  the  retroperitoneal  space  are
scarce,2± 4  and  recent  population-based figures are
not available. We therefore estimated incidence rates
of  STS  in  relation  to  other  primary  non-visceral
tumours in the retroperitoneum with the help of two
national registries.
Methods
Data on patients in The Netherlands with retroperi-
toneal  neoplasms  that  were  newly  diagnosed  and
confirmed histologically between 1 January 1989 and
1 January 1994 were retrieved from two sources.
The Netherlands Cancer Registry (NCR) manages
a  databank  with  information  on  all  patients  with
newly  diagnosed  cancers.  Malignancies  are  coded
according to the International Classification of Dis-
eases for Oncology.5 Data were provided on patients
identified within the NCR database as having retro-
peritoneally localised STS, seminoma (non-testicu-
lar), teratoma, and primary (epidermoid) carcinoma,
and were used to calculate their respective incidence.
Because of the aforementioned classification used
by the NCR,5 some malignant neoplasms that can
occur in the retroperitoneum are not topographically
identifiable as such (e.g. retroperitoneal lymphoma is
coded  topographically  as  an  abdominal  tumour).
Therefore, additional information was provided by6 Th. van Dalen et al.
The  Dutch  Network  and  National  Database  for
Pathology  (PALGA),  which  contains  standardised
abstracts of all pathology reports in The Netherlands,
with computerised data submission by the individual
pathology laboratories. The latter registry classifies
pathological  conditions according  to  the  Systema-
tized Nomenclature of Medicine (SNOMED, Amer-
ican College of Pathologists), and allows a search for
all malignant and benign neoplasms in the retroperi-
toneal space.
Crude incidence rates and age-specific incidence
rates for 10-year age groups were calculated per mil-
lion person-years for  males and  females using the
Dutch population on 1 July 1991 (7,478,911 males
and  7,648,088  females;  source,  Statistics  Nether-
lands).
Results
Seven hundred and six patients  were identified as
having a primary non-visceral retroperitoneal tumour
(Table  1).  The  majority  of  these  tumours was  of
malignant origin (n = 566; 80%). STS was the most
common non-visceral malignant tumour in the retro-
peritoneum  (n  =  192;  34%  of  the  malignant
tumours).  The  crude  incidence  of  retroperitoneal
STS was 2.5 per million person-years, and the male
to female ratio was 0.73. STS was the most common
malignant tumour in females (41%), followed by car-
cinoma  of  unknown  primary  tumour  site  (CUP)
(31%),  and malignant lymphoma (ML) (22%).  In
males, these proportions were 28 (STS), 30 (CUP),
and 32% (MI), respectively.
In Figure 1, the age-specific incidence of primary
Fig. 1. Primary (non-visceral) retroperitoneal tumours in (a) males and (b) females: age-specific incidence per million person-years 
in The Netherlands (1989± 1993).Soft tissue sarcoma as primary malignancy 7
non-visceral retroperitoneal tumours is delineated for
males and females. For convenience, benign retro-
peritoneal tumours were grouped together. The age-
specific incidence showed a similar pattern in both
sexes for all three common malignant tumours: an
increase in middle age followed by a levelling thereaf-
ter. In females, STS was more common than ML
irrespective of age, and only less frequent than CUP
in elderly women. CUP and ML more often occurred
in men than in women and, particularly in males aged
between 60 and 80 years, both CUP and ML more
commonly occurred than STS.
Discussion
In this population-based study, 80% of all primary
non-visceral  tumours in  the  retroperitoneum were
malignant. Soft tissue sarcomas comprised one-third
of the malignant tumours and were predominant in
females.  Malignant  lymphoma  and  carcinoma  of
unknown primary tumour site made up most of the
remainder. An age-related incidence rise was seen for
all three malignancy types in both sexes.
The  crude incidence of  2.5  per million person-
years resulted in 40 new patients with retroperitoneal
STS annually in the  Netherlands. In our country,
approximately 700 surgeons are affiliated to 110 hos-
pitals. This would imply that one patient with a ret-
roperitoneal STS is seen only once every 3 years in
the  average  surgical  practice,  assuming  that  all
patients with retroperitoneal STS are referred to sur-
geons. In reality, they are not all seen by surgeons
because some will be managed by other specialists
(e.g. urologists or gynaecologists).
This  unfamiliarity  with  STS  in  the  retroperito-
neum is likely to contribute to the difficulties in estab-
lishing the diagnosis correctly. In the aforementioned
population-based study,1 more than one-third of the
patients with a retroperitoneal STS was operated for
assumed  other  pathological  conditions;  STS  were
rarely if ever confused with malignant lymphomas or
carcinomas of unknown primary tumour site. They
were  rather  mixed  up  with  renal  carcinomas  and
tumours  of  the  female  reproductive  organs.  The
much higher incidence of the latter tumours (Table
2) is a probable explanation for this.
Yet, for the clinician who is examining a patient
with  a  retroperitoneal  tumour,  radiological  tech-
niques such as computed tomography or magnetic
resonance imaging/magnetic resonance angiography
should  readily  discriminate  visceral  from  non-vis-
ceral  neoplasms.6± 8  Subsequently,  pathological
examination  should  be  of  help  to  discriminate
between STS, malignant lymphoma, and carcinoma
of unknown primary site. Fine needle aspirates and
core needle biopsies may confirm the presence of a
STS,9± 11  but  the yield in the  case of STS is lim-
ited.10,12 More importantly, needle biopsies can reli-
ably  distinguish a  carcinoma of  unknown primary
tumour site,13 and the lymphoid nature of a retro-
peritoneal tumour.14,15 Hence, the main value of a
biopsy is to exclude the latter two malignancies and,
in that respect, the value of an open surgical biopsy
becomes questionable.
In conclusion, at the unusual occasion that a clini-
cian is confronted with a non-visceral neoplasm in
the retroperitoneal space, the tumour is most proba-
bly malignant, and a soft tissue sarcoma is relatively
Table 1. Crude incidence rates of non-visceral retroperitoneal tumours per million person-years in The Netherlands (1989± 1993)
Total 
(n)
incidence
(per 106 person-years)
Male to female
ratio
Malignant tumours (n = 556)
Soft tissue sarcoma 192 2.5 0.73
Carcinoma of unknown primary tumour site 172 2.3 1.04
Malignant lymphoma 154 2.0 1.52
Seminoma (non-testicular) 9 0.2* ±
Malignant teratoma 13 0.2 1.6
Primary (epidermoid) carcinoma 8 0.1 7
`Other’ 18 ± ±
Benign tumours (n = 140)
Lipoma 28 0.4 0.87
Schwannoma 24 0.3 0.25
Leiomyoma 21 0.3 0.05
Paraganglioma 12 0.2 3
Neurofibroma 8 0.1 0.33
Lymfangioma 8 0.1 1.67
Haemangioma 8 0.1 1
Ganglioneuroma 7 0.1 0.4
Neurilemmoma 6 0.1 0.5
Phaeochromocytoma (non-adrenal) 6 0.1 5
Other 12 ± 0.38
* Incidence per million person-years in men.8 Th. van Dalen et al.
common in comparison with other primary malig-
nancies. When a lymphoma or an unknown primary
carcinoma can be ruled out, a retroperitoneal mass
most likely is a soft tissue sarcoma. The clinical impli-
cation of this finding is important. Contrary to the
medical treatment of lymphomas and unknown pri-
mary  carcinomas,  surgery  is  the  main  therapeutic
modality  in  the  treatment  of  retroperitoneal  soft
tissue sarcoma. As a consequence, a retroperitoneal
mass of unknown nature deserves a secure perioper-
ative strategy assuming the presence of a STS.
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Table 2. Crude incidence rates of malignant tumours of the retroperitoneal and female reproductive organs per million person-years in 
The Netherlands (1989± 1993)16,17
Total
(n)
Incidence
(per 106 person-years)
Male to female
ratio
Renal carcinoma 6665 88.1 1.46
Adrenal carcinoma 231 3.1 0.94
Ureteric/pelvic carcinoma 1256 16.6 1.84
Pancreatic carcinoma 6772 89.5 1.04
Cancer of the ovary 6173 161.* ±
Cancer of the corpus uteri 6438 168.* ±
Retroperitoneal soft tissue sarcoma 192 2.5 0.73
* Incidence per million person-years in women.